To the editor,

Cholinergic urticaria (CholU), a subtype of chronic inducible urticaria (CIndU), is characterized by pinpoint, highly pruritic wheals with surrounding erythema caused by increased core body temperature.1 CIndU does not respond well to H1-antihistamines (H1AH).2,3 Omalizumab, a monoclonal antibody against immunoglobulin E, is a new therapeutic option for not only recalcitrant chronic spontaneous urticaria (CSU) but also various types of CIndU, including dermographism and cold urticaria.2-4 Omalizumab treatment for CholU has been reported mostly in Western countries.3,4 Here, we retrospectively analyzed omalizumab efficacy and its association with clinical characteristics in 27 H1AH-refractory CholU patients in Korea.

Twenty-seven CholU patients (mean age, 32.48; range, 17–69 years; male patients, 23 [85.2%]) were enrolled at the Department of Allergy of 3 university hospitals in Korea (Supplementary Methods). Six patients had combined CSU (21 had only CholU), and they were grouped into complete responders, partial responders, and non-responders according to their response to omalizumab using the visual analogue scale (VAS).

Omalizumab treatment in patients with Cholinergic Urticaria: A Real-World Retrospective Study in Korea

Ji Hye Kim,1 Hae-Sim Park,2 Young-Min Ye,2 Yoo Seob Shin,2 Hye-Ryun Kang,2 Soo Jie Chung,2 and Jeong-Hee Choi,3,4,5*
1Division of Pulmonology and Allergy, Konkuk University Hospital, Daejeon, Korea
2Department of Allergy and Clinical Immunology, Ajou University Hospital, Suwon, Korea
3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
4Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
5Allergy and Clinical Immunology Research Center, Hallym University College of Medicine, Chuncheon, Korea

Correspondence to
Jeong-Hee Choi MD, PhD
Department of Pulmonology and Allergy, Hallym University Dongtan Sacred Heart Hospital, 7 Keunjaebong-gil, Hwaseong 18450, Korea.
Tel: +82-31-8086-2928
Fax: +82-31-8086-2482
E-mail: mdqueen@hallym.or.kr

Copyright © 2020 The Korean Academy of Allergy, Allergy and Clinical Immunology - The Korean Academy of Pediatric Allergy and Respiratory Disease
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs
Ji Hye Kim https://orcid.org/0000-0003-4677-0513
Hae-Sim Park https://orcid.org/0000-0003-2614-0303
Young-Min Ye https://orcid.org/0000-0002-7517-1715
Yoo Seob Shin https://orcid.org/0000-0002-9855-3185
Hye-Ryun Kang https://orcid.org/0000-0002-2377-4201
Soo Jie Chung https://orcid.org/0000-0002-7777-1188
Jeong-Hee Choi https://orcid.org/0000-0002-0599-875X

https://e-aair.org
Disclosure
There are no financial or other issues that might lead to conflict of interest.

Omalizumab for Cholinergic Urticaria

Figure. Number of patients with CholU according to response to omalizumab treatment and omalizumab dosage (A). Number of patients with only CholU according to response to omalizumab treatment and omalizumab dosage (B). Response to omalizumab was assessed by patient global assessment using VAS (0–10 scale): a complete responder (0), a partial responder (VAS: 1–5), a non-responder (VAS: 6–10).
CholU, cholinergic urticaria; VAS, visual analogue scale.

response within 4 weeks after the final effective dose. There were no significant differences in clinical characteristics according to omalizumab responses (Supplementary Table S2).

Several case series have reported that CholU patients (from 62% to 75%) showed good response to omalizumab.4 Recently, larger case series involving 16 CholU patients reported 6 (37%) complete responders, 5 (31%) major responders, and 2 (13%) partial responders, where most patients had the responses within 6 weeks.5 Furthermore, 5 of 9 patients with CholU only (56%) were complete or major responders. In a randomized clinical trial involving 22 CholU patients, the negative rate of exercise challenge test was 31.3% at week 48, and daily symptoms score and VAS score progressively improved week 16 after treatment with 300 mg omalizumab.6 Our study showed that 19 (70.4%) of 27 CholU patients and 13 (61.9%) of 21 patients with CholU were partial or complete responders, providing indirect evidence for the good efficacy of omalizumab for H1AH-refractory CholU in an Asian country. Moreover, of 8 non-responders, 6 received only 150 mg omalizumab without up-dosing, and 5 received omalizumab only for 2 months. Three partial responders had their response at least 3 months after omalizumab treatment. Thus, higher dose and longer duration of omalizumab treatment may improve the outcome of omalizumab treatment in CholU.

In conclusion, this is the first study with the largest number of CholU in Asia, suggesting that omalizumab can be a good treatment option for H1AH-refractory CholU.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No.2018R1A2B6009178).
SUPPLEMENTARY MATERIALS

Supplementary Data S1
Methods

Click here to view

Supplementary Table S1
Clinical characteristics and omalizumab treatment of the study subjects

Click here to view

Supplementary Table S2
Comparison of clinical characteristics according to response to omalizumab treatment

Click here to view

REFERENCES


